ASML To Acquire Cymer To Accelerate Development Of EUV Technology
Business Wire
10/17/12 - 01:00 AM EDT
ASML Holding NV [ASML] (NASDAQ:ASML) (Amsterdam:ASML), a leading
provider of lithography systems for the semiconductor industry, and
Cymer, Inc. [CYMI] (Nasdaq: CYMI), a leading supplier of lithography
light sources used by chipmakers to manufacture advanced semiconductor
devices, announce that they have entered into a definitive agreement
under which ASML will acquire all outstanding shares of Cymer in a
cash-and-stock transaction currently valued at EUR 1.95 billion.
The purpose of the acquisition of Cymer is to accelerate the development
of Extreme Ultraviolet (EUV) semiconductor lithography technology. EUV
is vital to support the semiconductor industry’s transition to the next
manufacturing technology, which is needed to create microchips with more
functions at a lower cost and that are more energy-efficient, consistent
with Moore’s Law.
ASML and Cymer have collaborated closely for over a year, and this
merger is the natural evolution of their existing cooperation in
developing EUV technology. Combining Cymer’s expertise in EUV light
sources with ASML’s expertise in lithography systems design and
integration will reduce the risk and accelerate the introduction of this
extremely complex technology.
The transaction, which was unanimously approved by the boards of
directors of ASML and Cymer, would entitle each Cymer shareholder to
receive US$20.00 in cash and a fixed ratio of 1.1502 ASML ordinary
shares per Cymer share. The total price reflects a premium of 61 percent
over Cymer's 30-day volume-weighted average price (VWAP) and 52 percent
over its 90-day VWAP, using ASML’s VWAP for the comparable period ending
16 October 2012.
“We believe that this transaction will improve our capabilities to bring
new technologies to our customers, and will deliver value to Cymer’s and
ASML’s shareholders,” said Eric Meurice, President and Chief Executive
Officer of ASML. “We expect the merger to make EUV technology
development significantly more efficient and simplify the supply chain
and integration flow of the EUV modules. We are also very much
encouraged by the opportunities that we expect to create around Cymer’s
growing advanced Immersion systems and dry Deep Ultraviolet (DUV)
Installed Base Products (IBP) business.”
“Over the last several years, Cymer has been investing significant
capital towards developing EUV source technology. We are very encouraged
that ASML’s resources will enable the combined company to continue to
develop and successfully commercialize EUV on an accelerated time
frame,” said Bob Akins, Chairman and Chief Executive Officer of Cymer.
“The success of EUV is critical to the semiconductor industry, and we
view this merger as very attractive for our shareholders, customers and
employees as well as our industry.”
As a result of the transaction, ASML will also acquire Cymer’s DUV
business. This technology is expected to remain a significant and
growing engine of sales and profit and will be well positioned to
support and balance customer needs for EUV and immersion multiple
patterning. ASML intends to manage Cymer’s commercial operations as an
independent division based in the United States, and will continue to
deliver and service DUV and EUV sources for all customers on an arm’s
length basis. ASML scanners will continue to interface with light
sources from all manufacturers.
The transaction is expected to close in the first half of 2013 and is
subject to customary closing conditions, including review by U.S. and
international regulators and approval by Cymer's shareholders. Excluding
non-cash purchase price accounting adjustments, the transaction is
expected to be accretive to ASML's EPS in the second year after closing.
EUV status update
-
ASML’s 6 pre-production NXE:3100 EUV systems, capable of resolution
performance compatible with the 22 nm node in single patterning mode,
have exposed more than 23,000 wafers at customer sites with good
overlay and imaging performance, enabling semiconductor device recipe
development and confirmation of infrastructure progress. The successor
system, the NXE:3300B, is capable of resolution performance compatible
with the 14 nm node in single patterning mode. This system has already
shown overlay down to 1.3 nm and imaging down to 16 nm in a full-field
single exposure using new illumination technology. Progress continues
on improving the productivity of the EUV systems currently limited by
the light source.
-
Cymer’s EUV light sources have for some time been exposing wafers at
up to 11 Watts source power at customer facilities, resulting in
NXE:3100 productivity of up to 7 wafers per hour. ASML and Cymer
jointly made significant progress during the summer and have now
proven in laboratories a sustained 30-Watt source exposure power
potential, which would enable the NXE:3300B to expose 18 wafers per
hour. ASML’s specified target remains at 105 Watts or 69 wafers per
hour (wph), to be achieved for 2014 microchip production.
-
ASML and Cymer have been cooperating very closely for more than a year
on a number of development tasks. The transaction is a natural next
step from the R&D collaboration and will make the cooperation more
efficient by knitting development teams closer together, streamlining
project management and simplifying the supply chain.
The current accumulated EUV exposure experience at customers, the
successful demonstration of the NXE:3300B imaging and overlay and the
proof of concept of up to 30 Watts source power are expected to support
the following plan:
|
1.
|
The deliveries of the first 11 NXE:3300B systems in 2013 to be
installed at customers for R&D.
|
|
2.
|
Additional orders for NXE:3300B systems intended for production in
2014 at a minimum specification targeting 69 wph. ASML has currently
received 4 commitments and expects another 4 to 8 within the next 6
months.
|
About ASML
ASML is one of the world's leading providers of lithography systems for
the semiconductor industry, manufacturing complex machines that are
critical to the production of integrated circuits or chips.
Headquartered in Veldhoven, the Netherlands, ASML is traded on Euronext
Amsterdam and NASDAQ under the symbol ASML. ASML has more than 8,200
employees on payroll (expressed in full time equivalents), serving chip
manufacturers in more than 55 locations in 16 countries. More
information about our company, our products and technology, and career
opportunities is available on our website:
www.asml.com
About Cymer
Cymer, Inc. (Nasdaq: CYMI) is an industry leader in developing
lithography light sources, used by chipmakers worldwide to pattern
advanced semiconductor chips, and is pioneering a new silicon
crystallization tool for the display industry. Cymer’s light sources
have been widely adopted by the world’s top chipmakers and the company’s
installed base comprises approximately 3,750 systems. Continuing its
legacy of leadership, Cymer is currently pioneering the industry’s
transition to EUV lithography, the next viable step on the technology
roadmap for the creation of smaller, faster chips. The company is
headquartered in San Diego, CA, has more than 1,200 employees on payroll
(expressed in full time equivalents) and supports its customers from
numerous offices around the globe. Cymer maintains a Web site to which
it regularly posts press releases, SEC filings, and additional
information about Cymer. Interested persons can also subscribe to
automated e-mail alerts or RSS feeds. Please visit
www.cymer.com
Forward Looking Statements
“Safe Harbor” Statement under the US Private Securities Litigation
Reform Act of 1995: this press release contains statements that
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements, as they
relate to Cymer or ASML, this transaction or the expected benefits of
this transaction, involve risks and uncertainties that may cause results
to differ materially from those set forth in the statements. We use
words such as “anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance” and similar expressions
to identify these forward-looking statements. These statements are not
historical facts, but rather are based on current expectations,
estimates, assumptions and projections about the business and future
financial results of ASML and Cymer, and readers should not place undue
reliance on them. Actual results or developments may differ materially
from those in the forward-looking statements. These forward looking
statements are subject to risks and uncertainties, including the
inability to obtain Cymer shareholder approval or regulatory approval
for this transaction, the satisfaction of other conditions to the
closing of the transaction, the possibility that the length of time
necessary to consummate this transaction may be longer than anticipated,
the achievement of the expected benefits of the transaction, risks
associated with integrating the businesses of Cymer and ASML, the
possibility that the businesses of ASML and Cymer may suffer as a result
of uncertainty surrounding the proposed transaction, the expected
capacity and capability developments in EUV systems, the anticipated
effect of this transaction on ASML’s earnings per share and EUV margins,
the benefits of the DUV and IBP businesses and other risks associated
with the development of EUV technology.
The foregoing risk list of factors is not exhaustive. You should
consider carefully the foregoing factors and the other risks and
uncertainties that affect the businesses of ASML and Cymer described in
the risk factors included in ASML's Annual Report on Form 20-F and
Cymer’s Annual Report on Form 10-K, Cymer’s Quarterly Reports on Form
10-Q, and other documents filed by ASML and Cymer from time to time with
the SEC. The parties disclaim any obligation to update the
forward-looking statements contained herein.
Important Information for Investors and Stockholders
This communication does not constitute an offer to sell or the
solicitation of an offer to buy any securities or a solicitation of any
vote or approval. No offer of securities shall be made except by means
of a prospectus meeting the requirements of Section 10 of the Securities
Act of 1933, as amended. The proposed transaction will be submitted to
the stockholders of Cymer for their consideration. In connection with
the proposed transaction, Cymer will file a proxy statement with the SEC
and ASML will file a registration statement on Form F-4 with additional
information concerning the transaction, including a proxy
statement/prospectus. CYMER STOCKHOLDERS ARE ADVISED TO READ THESE
DOCUMENTS CAREFULLY (WHEN THEY BECOME AVAILABLE) AND ANY OTHER RELEVANT
DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS
TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. The
proxy statement, the registration statement, and other documents
containing other important information about Cymer and ASML filed or
furnished to the SEC (when they become available) may be read and copied
at the SEC’s public reference room located at 100 F Street, N.E.,
Washington, D.C. 20549. Information on the operation of the Public
Reference Rooms may be obtained by calling the SEC at 1-800-SEC-0330.
The SEC also maintains a website,
www.sec.gov,
from which any electronic filings made by ASML and Cymer may be obtained
without charge. In addition, investors and shareholders may obtain
copies of the documents filed with or furnished to the SEC upon oral or
written request without charge. Requests may be made in writing by
regular mail by contacting ASML at the following address: De Run 6501,
5504 DR, Veldhoven, The Netherlands, Attention: Investor Relations, or
by contacting Cymer at the following address: 17075 Thornmint Court, San
Diego, CA, 92127, Attention: Investor Relations, +1 858 385 6097.
Cymer and ASML and their respective directors, executive officers and
employees and other persons may be deemed to be participants in the
solicitation of proxies in respect of the transaction. Information
regarding Cymer's directors and executive officers and their ownership
of Cymer common stock is available in Cymer’s proxy statement for its
2012 meeting of stockholders, as filed with the SEC of Schedule 14A on
April 11, 2012. Information about ASML's directors and executive
officers and their ownership of ASML ordinary shares is available in its
Annual Report on Form 20-F for the year ended December 31, 2011 and will
be available in the joint proxy statement/prospectus (when available).
Other information regarding the interests of such individuals as well as
information regarding Cymer's and ASML's directors and officers will be
available in the proxy statement/prospectus when it becomes available.
These documents can be obtained free of charge from the sources
indicated above.